Where does Palvella Therapeutics's cash flow data come from?

Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$15.77M-24.0%	-$12.71M-12.1%	-$11.35M-19.8%	-$9.47M-15.7%	-$8.19M-35.0%
Stock-based compensation	$3.38M+62.0%	$2.08M+16.4%	$1.79M+24.9%	$1.43M+31.0%	$1.09M+308%
Change in accounts payable	$851K-26.4%	$1.16M—	——	$116K-89.7%	$1.12M+2,514%
Change in accrued liabilities	-$900K—	——	——	——	-$2.91M—
Change in other assets	$357K+261%	-$222K-22.0%	-$182K-29.1%	-$141K+82.8%	-$819K-165%
Loss on extinguishment of debt	——	——	——	——	——
Change in operating lease liabilities	-$49K—	——	——	——	$0—
Net cash from operating activities	-$10.86M-121%	-$4.93M+37.5%	-$7.88M-45.0%	-$5.43M+19.7%	-$6.77M-25.5%
Net cash from investing activities	-$55.44M—	——	——	——	$0—
Proceeds from issuance of common stock	$230M+218,948%	$105K-56.6%	$242K-41.8%	$416K—	$0—
Other financing activities	$1.98M—	——	——	——	$0—
Payment of debt issuance costs	$14.25M—	——	——	——	$0—
Net cash from financing activities	$214.73M+438,327%	-$49K—	——	——	-$1.2M-102%
Effect of exchange rate changes on cash	-$15K—	——	$770K+813%	-$108K-1,700%	-$6K-300%
Net increase (decrease) in cash	$148.41M+2,757%	-$5.59M+18.7%	-$6.87M-32.2%	-$5.19M+34.9%	-$7.98M-111%
Accretion (Amortization) of Discounts and Premiums, Investments	$15K—	——	——	——	$0—
Accounts payable	$851K-26.4%	$1.16M—	——	$116K-89.7%	$1.12M+2,514%
Accrued expenses and other liabilities	-$900K—	——	——	——	-$2.91M—
Increase Decrease In Derivative Liabilities	$116K-2.5%	$119K+45.1%	$82K-30.5%	$118K+57.3%	$75K-67.2%
Operating lease liabilities	-$49K—	——	——	——	$0—
Increase (Decrease) in Prepaid Expense and Other Assets	$357K+261%	-$222K-22.0%	-$182K-29.1%	-$141K+82.8%	-$819K-165%
Payments Of Stock Issuance Costs	——	$38.5K0.0%	$38.5K0.0%	$38.5K0.0%	$38.5K—
Cash Acquired From Reverse Merger Transaction	——	$0—	$0—	$0—	$0-100%
Increase Decrease In Operating Lease Liability	-$49K—	——	——	——	$0—
Increase Decrease In Research And Development Tax Credit Receivables	——	-$526.25K0.0%	-$526.25K0.0%	-$526.25K0.0%	-$526.25K-206%
Non Cash Lease Operating Expense	$44K—	——	——	——	$0—
Noncash Interest Expense Income Royalty Agreement	$2.04M—	——	——	——	$1.22M+25.0%
Payment For Contingent Consideration Liability Financing Activities	$1.98M—	——	——	——	$0—
Payments Of Merger Related Costs Financing Activities	$0—	——	——	——	$1.27M-48.7%
Payments Of Transaction Costs Associated With Pipe Financing	——	$0—	$0—	$0—	$0-100%
Transaction Costs Related To Reverse Merger Included In Accounts Payable And Accrued Expenses	——	$0—	$0—	$0—	$0-100%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Palvella Therapeutics's cash flow data come from?: Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.